Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

NRF commits R30-million for research at the UFS
2007-02-20

The National Research Foundation (NRF) has committed approximately R30-million for various research projects at the University of the Free State (UFS).
 
According to Prof Frans Swanepoel, Director of Research Development at the UFS, the NRF has also approved all eight research niche areas that were submitted to the NRF, the highest number approved at any university in the country.
 
Prof Swanepoel said the 24 research projects for which funding had been obtained from the NRF ranged from traditional healing and HIV/Aids/tuberculosis management, practices of the paediatric anti-retroviral programme at the UFS to nano-materials synthesis and characterisation.
 
He said the eight research niche areas were part of an initiative at the UFS to establish strategic clusters of academic and research excellence.
 
“There will be six strategic academic clusters at the UFS and the eight NRF-approved research niche areas will form part of them,” Prof Swanepoel said.
 
The six strategic clusters are:
1.         Water management in water-scarce areas
2.         New frontiers in poverty reduction and sustainable development
3.         Social transformation in diverse societies
4.         Ecologically sound value chains for agricultural commodities
5.         Materials and nano sciences
6.         Advanced bio-molecular research
 
Prof Swanepoel said that the UFS had also submitted five proposals in terms of an NRF initiative to establish research chairs at South African universities.
 
“Linked to our intention to establish six strategic academic clusters, five proposals for the South African Research Chair Initiative (SARCHi) were submitted. All five pre-proposals were accepted in the first round of screening, and successful candidates have been invited to submit full proposals by the end of February,” he said.
 
The proposed research chairs are:
 
Petro- and organometallic chemistry
Biocatalytic and biomimetic oxidation-reduction systems
Nano-solid state lighting
People’s health and well-being
Water management
 
Speaking at the official opening of the university earlier this month, the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, said: “The cluster initiative represents a strategic initiative to focus our energies in a few key areas, investing in them so that the UFS can become an international leader in those fields.”
 
“A medium sized university such as the UFS with relatively limited human, physical and financial resources has to achieve this kind of ‘critical mass’ and synergy to establish itself in terms of its core functions of teaching/learning, research and community engagement,” said Prof Fourie.
 
Media release
Issued by: Lacea Loader
Media Representative
Tel: 051 401 2584
Cell: 083 645 2454
20 February 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept